Immuno-oncology targets

TARGET DISEASE INDICATIONS STATUS – KEY DATA MILESTONE

ZM008

Lead Asset
Anti-LLT1 mAb
(Potential first-in-class antibody targeting LLT1-Lectin Like Transcript 1)

Prostate Cancer,
B cell lymphoma, Glioblastoma, Rheumatoid Arthritis
  • Strong in-vitro and in-vivo preclinical data demonstrates tumor cell death, immune cell infiltration and tumor growth inhibition
  • Completed transfer to Catalent-produced Tox material
  • Patient tissue data analysis at Mount Sinai and HCG in progress
  • Development on track for Investigational New Drug (IND) filing in mid CY2021
  • Phase I clinical trials readiness likely by Q3 2021

ZM012

mAb target. Functions through tumour associated antigen/NK cell receptor

Lymphoma and other Undisclosed indications
  • Unique Clone identification in process
Animal Efficacy –
Q2 2021

ZM014

mAb target. Functions through tumour NK cell receptor

Lymphoma
  • Unique Clone identification in process
Animal Efficacy –
Q 4 2020

2

Molecules for NK cell and cell targets under development

Future targets of interest

Other Innate Immunity Targets

Novel Targets

Academic collaboration in the US